Carfilzomib: Additional Phase II data

Additional data from 51 evaluable Velcade bortezomib-naïve patients in the ongoing, open-label, North American Phase II PX-171-004 trial showed that 20 mg/m 2 IV carfilzomib produced an overall response rate of 45%, including 1 complete response, 4 very good partial responses and 18 partial responses. An additional 9 patients had minor responses and 10 patients had stable disease for >=6 weeks. Data will be presented at the American Society of Hematology meeting in New Orleans in December. ...